N/A
Completed N=12
A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling
Source: ClinicalTrials.gov NCT01740817 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcomePrimary: Muscle Insulin Sensitivity-M Value — 9.9; 8.3 mg/kg.min
Summary
The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Muscle Insulin Sensitivity-M Value |
9.9; 8.3 | — |
| SECONDARY TLR4 Messenger Ribonucleic Acid (mRNA) in Muscle |
1; 1.6 | — |
| SECONDARY Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle |
1.0; 1.95 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must have the following laboratory values: Hematocrit ≥ 35%, serum creatinine ≤ 1.5 mg/dl, aspartate aminotransferase (AST) 170, diastolic BP>95), resting heart rate >100, electrolyte abnormalities, neuromuscular or musculoskeletal disease.
- Subjects who smoke.
- Subjects who engage in a regular exercise program (zero or one exercise sessions per week are allowed).
- Any subject who has donated blood in the previous two months.
- Any subject with a hematocrit of less than 35.
- Subjects who are claustrophobic.
- Women taking oral contraceptives.
- alcohol consumption greater than 30 grams daily.
- baseline plasma triglyceride levels over 200 mg/dl
Data sourced from ClinicalTrials.gov (NCT01740817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.